Existing backers Bay City Capital, Canaan Partners and Fountain Healthcare Partners also laid down capital for the Series C round.
Civitas Therapeutics develops transformative therapeutics to help relieve symptoms associated with Parkinson’s disease.
The company said the proceeds will be used for the upcoming Phase 3 clinical trials for its lead product CVT-301.
In July AltAssets reported that biotechnology-focused Sofinnova Ventures is targeting up to $500m for its ninth vehicle. The firm’s Fund VIII closed on $440m.
Copyright © 2014 AltAssets